Kunnath Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -98.87%
- Profit Growth 0.11%
- Ebitda -0.00%
- Net Worth -4.66%
- Total Assets -33.12%
About Kunnath Pharmaceuticals
Kunnath Pharmaceuticals Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 September 2006 and has a history of 18 years and four months. Its registered office is in Ernakulam, Kerala, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Lissa Abraham, Liya Abraham, Lida Abraham, and One other member serve as directors at the Company.
Company Details
-
Location
Ernakulam, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232KL2006PTC019825
-
Company No.
019825
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Sep 2006
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Kunnath Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lissa Abraham
|
Director | 24-Mar-2021 | Current |
|
Liya Abraham
|
Director | 20-Oct-2018 | Current |
|
Lida Abraham
|
Director | 24-Mar-2021 | Current |
|
Lidiya Abraham
|
Director | 24-Mar-2021 | Current |
Financial Performance of Kunnath Pharmaceuticals.
Kunnath Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 98.87% decrease. The company also saw a slight improvement in profitability, with a 0.11% increase in profit. The company's net worth dipped by a decrease of 4.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kunnath Pharmaceuticals?
In 2019, Kunnath Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kunnath Ayur Private LimitedLissa Abraham, Liya Abraham and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kunnath Pharmaceuticals?
Unlock and access historical data on people associated with Kunnath Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kunnath Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kunnath Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
